Evidence map›Paper›PMID 22591037›Full record

ReviewAlimentary pharmacology & therapeutics2012

Review article: current treatment options and management of functional dyspepsia.

B E Lacy, N J Talley, G R Locke, E P Bouras, J K DiBaise, H B El-Serag, B P Abraham, C W Howden, P Moayyedi, C Prather

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alimentary pharmacology & therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05004012 (AnX/Ankon Navicam Magnetically Controlled Capsule Endoscopy Feasibility Study in Gastric Motility), which is not on this map. Cited by 91 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 8 pooled it
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05004012 nacompletednot on this mapstarted 2021, after this paper: background citation

AnX/Ankon Navicam Magnetically Controlled Capsule Endoscopy Feasibility Study in Gastric Motility

TypeinterventionalSponsorUniversity of California, Los AngelesRan2021 to 2023Enrolled20ConditionsGastroparesis, DyspepsiaArmsMagnetically Controlled Capsule Endoscopy
3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 8 syntheses or guidelines pooled it, 211 citations in OpenAlex.

  1. Non-Chinese herbal medicines for functional dyspepsia.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Prokinetics for functional dyspepsia.The Cochrane database of systematic reviews · 2018
    Pooled it
  3. Proton pump inhibitors for functional dyspepsia.The Cochrane database of systematic reviews · 2017
    Pooled it
  4. Pooled it
  5. ACG and CAG Clinical Guideline: Management of Dyspepsia.The American journal of gastroenterology · 2017
    Guideline
  6. Proton pump inhibitors for functional dyspepsia.The Cochrane database of systematic reviews · 2017
    Pooled it
  7. Pooled it
  8. ACG clinical guidelines: diagnosis and management of celiac disease.The American journal of gastroenterology · 2013
    Guideline
  9. Trial
  10. Trial
  11. Trial
  12. Female Gender is a Poor Predictive Factor of Functional Dyspepsia Resolution afterThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2018
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 3 countries.

B E LacyDartmouth-Hitchcock Medical Center, Lebanon, NH, USA. brian.lacy@hitchcock.org
N J Talley
G R Locke
E P Bouras
J K DiBaise
H B El-Serag
B P Abraham
C W Howden
P Moayyedi
C Prather
Baylor College of Medicine · USDartmouth–Hitchcock Medical Center · USMayo Clinic · USMayo Clinic in Arizona · USMcMaster University Medical Centre · CANorthwestern University · USSaint Louis University · USUniversity of Newcastle Australia · AUWinnMed · US

Funding

Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Geoffrey A Preidis · 2001 to 2026
$28.3M
Antidepressant Therapy for Functional DyspepsiaU01DK065713 · NIDDK · MAYO CLINIC ROCHESTER · PI LOCKE, GILES RICHARD · 2005 to 2011
$5.0M
NIDDK NIH HHS P30 DK056338NIDDK NIH HHS P30 DK56338NIDDK NIH HHS U01 DK065713NIDDK NIH HHS U01DK065713
6 · The paper itself

Abstract

backgroundFunctional dyspepsia (FD), a common functional gastrointestinal disorder, is defined by the Rome III criteria as symptoms of epigastric pain or discomfort (prevalence in FD of 89-90%), postprandial fullness (75-88%), and early satiety (50-82%) within the last 3 months with symptom onset at least 6 months earlier. Patients cannot have any evidence of structural disease to explain symptoms and predominant symptoms of gastroesophageal reflux are exclusionary. Symptoms of FD are non-specific and the pathophysiology is diverse, which explains in part why a universally effective treatment for FD remains elusive.

aimTo present current management options for the treatment of FD (therapeutic gain/response rate noted when available).

resultsThe utility of Helicobacter pylori eradication for the treatment of FD is modest (6-14% therapeutic gain), while the therapeutic efficacy of proton pump inhibitors (PPI) (7-10% therapeutic gain), histamine-type-2-receptor antagonists (8-35% therapeutic gain), prokinetic agents (18-45%), tricyclic antidepressants (TCA) (response rates of 64-70%), serotonin reuptake inhibitors (no better than placebo) is limited and hampered by inadequate data. This review discusses dietary interventions and analyses studies involving complementary and alternative medications, and psychological therapies.

conclusionsA reasonable treatment approach based on current evidence is to initiate therapy with a daily PPI in H. pylori-negative FD patients. If symptoms persist, a therapeutic trial with a tricyclic antidepressant may be initiated. If symptoms continue, the clinician can possibly initiate therapy with an anti-nociceptive agent, a prokinetic agent, or some form of complementary and alternative medications, although evidence from prospective studies to support this approach is limited.

Indexed as

AnalgesicsAntidepressive Agents, TricyclicComplementary TherapiesDietary SupplementsDyspepsiaGastrointestinal AgentsHelicobacter InfectionsHelicobacter pyloriHistamine H2 AntagonistsHumansProton Pump InhibitorsPsychotherapyTreatment OutcomeAnalgesicsAntidepressive Agents, TricyclicGastrointestinal AgentsHistamine H2 AntagonistsProton Pump Inhibitors

Identifiers

PMID22591037
PMCPMC3970847
OpenAlexW2034282428

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.